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Mutations in a recently discovered family of proteinkinases are responsible for an autosomal-dominantform of inherited hypertension, known as Gordon’s
syndrome or pseudohypoaldosteronism type II (PHAII).1 The
phenotype also includes hyperkalemia and hyperchloremic
metabolic acidosis.1 The name of this kinase family is WNK
(with no lysine [K]) because of the absence of a lysine in
subdomain II of the enzymes.2 WNK1 and WNK4, located in
human chromosomes 12 and 17, respectively, are predomi-
nantly expressed in the distal convoluted tubules and the
collecting ducts of the kidney.1
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In vitro, wild-type WNK4 inhibits the thiazide-sensitive
sodium chloride cotransporter (NCCT)3,4 and the renal outer
medullary potassium ion channel (ROMK),5 but increases
paracellular chloride permeability.6 Some WNK4 mutations
identified in PHAII behave as a loss of function for the NCCT
inhibition3,4,7 but as a gain of function for the inhibition of
ROMK,5,7 and further stimulate paracellular chloride trans-
port.6,8 These effects of WNK4 mutations fit well with the
proposed mechanisms for the development of hypertension
and electrolyte abnormalities in PHAII. Furthermore, in vitro,
WNK1 counteracts the inhibition of NCCT by WNK44 and
activates the serum- and glucocorticoid-inducible protein
kinase (SGK1), which in turn stimulates the epithelial sodium
channel (ENaC).9 The observation that heterozygous WNK1-
deficient mice had lower blood pressure than wild-type
control animals further supports the role of WNK1 in blood
pressure regulation.10 The evidence from studies in patients
with PHAII,1 cell models,3–9 and genetically engineered
animals10 makes WNK1 and WNK4 strong candidates possi-
bly involved in the pathogenesis of essential hypertension.
However, previous case-control11–13 and population-based14
studies of various single nucleotide polymorphisms (SNPs) in
WNK1 and WNK4 yielded inconsistent results.
The study published by Tobin and colleagues15 in this issue
of Circulation may herald a breakthrough in unraveling the
putative association between blood pressure and genetic
variation in the WNK kinases. The authors recruited via
family practitioners a family-based sample of nuclear fami-
lies consisting of both parents and 2 offspring, which was
representative of the general population of Leicestershire,
UK. A history of hypertension was not among the inclusion
criteria. The researchers employed 26-hour ambulatory mon-
itoring to measure the blood pressure phenotypes. Compared
with conventional blood pressure measurement, ambulatory
monitoring is characterized by high reproducibility, is not
subject to digit preference and observer bias, and avoids the
so-called white coat effect, which is the transient rise in a
subject’s blood pressure in response to the clinical surround-
ings or the presence of an observer. The authors discarded the
first 2 hours of each ambulatory recording to avoid any
alerting response. In addition to the precision of the pheno-
type, Tobin and colleagues extensively genotyped 9 SNPs in
WNK1, 8 of which were sufficient to predict the common
haplotypes. They also measured 1 intronic SNP in WNK4,
which is frequent among white Europeans. The heritability of
the 24-hour systolic and diastolic blood pressure was around
65%. The authors found statistically significant associations
of mean 24-hour systolic and/or diastolic blood pressures
with several common SNPs and haplotypes in WNK1. The
mean estimated effect sizes for single SNPs approximately
ranged from a 2-mm Hg reduction to a 1-mm Hg increase. In
contrast, there was no association between blood pressure and
the SNP in WNK4. All findings remained consistent after
adjustment for sex, age, body mass index, smoking, alcohol
intake, history of hypercholesterolemia, and education level.
The demonstration that common variants in WNK1, a gene
causing a rare monogenic form of hypertension, contributes
to the blood pressure variation in the general population is a
genuine breakthrough.
Whereas the study by Tobin and colleagues15 lifts a corner
of the veil surrounding the WNK paradigm, it also leaves
several questions unanswered. First, the authors did not
measure serum concentration or 24-hour excretion of electro-
lytes, nor the circulating components of the renin-angiotensin
system. WNKs are widely expressed in epithelia.16,17 Their
study15 therefore does not prove with absolute certainty that
the association with blood pressure was renally mediated,
although the latter hypothesis is most likely in view of the
previous evidence.4,9 Second, the genetic epidemiological
findings are not underpinned by in vitro studies proving
functionality of the WNK1 haplotypes in renal tubular cells.
Third, the findings by Tobin et al15 are at variance with
another recent report14 published by the same investigators.
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Indeed, family-based association tests involving 712 severely
hypertensive families in the British Genetics of Hypertension
(BRIGHT) Study14 showed significantly positive associations
of systolic (z2.241, P0.025) and diastolic (z1.992,
P0.046) blood pressures with the rs1468326 SNP in WNK1,
and a negative association of systolic (z2.300, P0.017)
blood pressure with the WNK1 haplotype h10 AGCCTCCG.
In the present study, these associations had an opposite sign
and did not reach statistical significance.15 This was also the
case for the common WNK1 haplotype h4 CACCCCCG,
which was positively correlated with systolic pressure
(z1.912, P0.053) in the BRIGHT study14 but negatively
with systolic and diastolic pressures during daytime and over
24 hours (z2.142; P0.032).15 These contradictory re-
sults require clarification. Fourth, Tobin and colleagues15 did
not investigate the possible interaction between genetic vari-
ation in the WNKs and salt intake in relation to blood
pressure. The European Project on Genes in Hypertension18
highlighted that phenotype–genotype relationships strongly
depend on lifestyle, in particular salt intake, as reflected by
the 24-hour urinary excretion of sodium. Ignoring such
interaction may explain the aforementioned inconsistencies.
Irrespective of its limitations, the present study15 is the first
study that demonstrates that common genetic variants of
WNK1 contribute to blood pressure variation in a general
white population. If these findings are confirmed by other
epidemiological studies and if they are supported by experi-
mental evidence for functionality, then they may have wide-
ranging implications. WNK kinases may become novel targets
for pharmaceutical intervention and lead to the development
of diuretic agents without the metabolic side effects of
thiazides. Moreover, further studies should address the ques-
tion to what extent genetic variation in the WNKs influences
salt sensitivity and the response to antihypertensive drugs and
whether they can predict the incidence of hypertension and
cardiovascular morbidity and mortality. Thus, the article by
Tobin and colleagues15 is a significant step forward, but the
onward journey to the possible clinical applications of the
WNK paradigm remains long.
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Association of WNK1 Gene Polymorphisms and Haplotypes
With Ambulatory Blood Pressure in the General Population
Martin D. Tobin, PhD; Stuart M. Raleigh, PhD; Stephen Newhouse, MSc; Peter Braund, MSc;
Clare Bodycote, BSc; Jenny Ogleby, BSc; Deborah Cross, PhD; Jay Gracey, BA; Saija Hayes, BSc;
Terry Smith, RGN; Cathy Ridge, BA; Mark Caulfield, FRCP; Nuala A. Sheehan, PhD;
Patricia B. Munroe, PhD; Paul R. Burton, MD; Nilesh J. Samani, MD
Background—Blood pressure (BP) is a heritable trait of major public health concern. The WNK1 and WNK4 genes, which
encode proteins in the WNK family of serine-threonine kinases, are involved in renal electrolyte homeostasis. Mutations
in the WNK1 and WNK4 genes cause a rare monogenic hypertensive syndrome, pseudohypoaldosteronism type II. We
investigated whether polymorphisms in these WNK genes influence BP in the general population.
Methods and Results—Associations between 9 single-nucleotide polymorphisms (SNPs) in WNK1 and 1 in WNK4 with
ambulatory BP were studied in a population-based sample of 996 subjects from 250 white European families. The
heritability estimates of mean 24-hour systolic BP (SBP) and diastolic BP (DBP) were 63.4% and 67.9%, respectively.
We found statistically significant (P0.05) associations of several common SNPs and haplotypes in WNK1 with mean
24-hour SBP and/or DBP. The minor allele (C) of rs880054, with a frequency of 44%, reduced mean 24-hour SBP and
DBP by 1.37 (95% confidence interval, 2.45 to 0.23) and 1.14 (95% confidence interval, 1.93 to 0.38) mm Hg,
respectively, per copy of the allele.
Conclusions—Common variants in WNK1 contribute to BP variation in the general population. This study shows that a
gene causing a rare monogenic form of hypertension also plays a significant role in BP regulation in the general
population. The findings provide a basis to identify functional variants of WNK1, elucidate any interactions of these
variants with dietary intake or with response to antihypertensive drugs, and determine their impact on cardiovascular
morbidity and mortality. (Circulation. 2005;112:3423-3429.)
Key Words: blood pressure  genetics  hypertension  kidney  risk factors
Blood pressure (BP) is a key determinant of cardiovascu-lar health.1,2 Familial aggregation of BP has long been
recognized, and estimates of the heritability of systolic (SBP)
and diastolic (DBP) BP have exceeded 50%.3,4 The identifi-
cation of genes involved in BP regulation, by improving
knowledge of the relevant biology, should facilitate advances
in treatment and control of BP. However, BP is a complex
trait, and genetic studies into its etiology are constrained by
the small effect sizes of the individual genetic variants,
imprecise measures of the phenotype, and low-power ap-
proaches to study design and analysis.
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Studies of monogenic syndromes have provided important
insights into a number of mechanisms underlying BP regu-
lation.5 Although these provide evidence for a causal relation
between gene and disease, none of these genes have yet been
shown to directly affect BP in the general population.5
Recently, mutations in the WNK1 and WNK4 genes, which
encode proteins in the WNK (“with no lysine” [K]) family of
serine-threonine kinases, have been shown to cause
pseudohypoaldosteronism type II (PHAII, or Gordon’s syn-
drome), an autosomal-dominant condition characterized by
hypertension and hyperkalaemia.6 The WNK1 and WNK4
proteins localize to distal nephrons, WNK1 normally inhib-
iting WNK4 and WNK4 normally inhibiting the Na-Cl
cotransporter in the apical membrane of epithelial cells lining
the distal convoluted tubule.7,8 Thus, “gain-in-function” mu-
tations in WNK1 or “loss-of-function” mutations in WNK4
result in PHAII that involves Na-Cl cotransporter overactiv-
ity.7,8 The Na-Cl cotransporter is sensitive to thiazide diuret-
ics, and patients with PHAII exhibit an unusually large BP
fall in response to thiazides.9
Received April 12, 2005; revision received July 26, 2005; accepted August 22, 2005.
From the Department of Health Sciences (M.D.T., N.A.S., P.R.B.), University of Leicester; the Department of Cardiovascular Sciences (S.M.R., P.B.,
C.B., J.O., D.C., J.G., S.H., T.S., C.R., N.J.S.), University of Leicester, Glenfield Hospital; and the Department of Genetics (M.D.T., N.A.S., P.R.B.),
University of Leicester, Leicester; and the Department of Clinical Pharmacology and Barts and the London Genome Centre (S.N., M.C., P.B.M.), Barts
and the London School of Medicine, London, England.
The online-only Data Supplement can be found at http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.105.555474/DC1.
Correspondence to Prof Nilesh J. Samani, Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital,
Groby Road, Leicester LE3 9QP, UK. E-mail njs@le.ac.uk
© 2005 American Heart Association, Inc.
Circulation is available at http://www.circulationaha.org DOI: 10.1161/CIRCULATIONAHA.105.555474
3423
Hypertension
WNK1 spans 156 kb of genomic DNA, with at least 28
exons producing multiple transcripts owing to alternative
splicing, and is highly polymorphic, with 100 validated
single-nucleotide polymorphisms (SNPs) (dbSNP, build 124;
available at http://www.ncbi.nlm.nih.gov/projects/SNP/; last
accessed February 11, 2005). WNK4 spans 16 kb of genomic
DNA and 19 exons and, in white European subjects, is much
less polymorphic, with only 1 common SNP reported
(1156666G3A).10
A few studies have examined the association of poly-
morphisms in WNK1 and/or WNK4 with the risk of hyper-
tension.10–13 A study in Japanese subjects found a nominal
association with hypertension and 1 WNK4 SNP
(C14717T).11 Although an association between another
WNK4 SNP (1156666G3A) and hypertension has been
reported in white American subjects,10 this finding was not
replicated in a study of white Australian subjects,12 but both
studies were small. Recently, the BRIGHT study provided
evidence supporting a possible association between a WNK1
SNP (rs1468326) and the severity of hypertension in a family
study of extremely hypertensive white European subjects.13
However, no study has yet examined whether common
variants in WNK1 or WNK4 are associated with BP regulation
in a population-based sample that has not been selected for
the presence or absence of hypertension.
The main objective of our study was to investigate the
association between common SNPs in WNK1 with BP in a
population-based sample. Because BP measured at a single
time is subject to transient variation and because BP exhibits
circadian variations, we measured ambulatory BP for 24
hours to characterize it more precisely and to maximize the
power to detect genetic determinants with a modest effect on
BP. For completeness, we also included in our investigation
the single WNK4 SNP observed in white European
populations.10
Methods
Subjects and Phenotyping
We studied 1005 white European subjects from 252 nuclear families
recruited from the general population in the ongoing GRAPHIC
(Genetic Regulation of Arterial Pressure of Humans in the Commu-
nity) study.
Families were included if both parents aged 40 to 60 years and 2
offspring 18 years wished to participate. Families were recruited
by writing to women aged 40 to 59 years who had registered with
participating family practitioners in Leicestershire, England, inviting
them and their families to take part. Subjects were excluded if they
had renal disease or a comorbidity that affected accurate BP
measurement. There was no preferential selection based on history of
hypertension. Interviews by research nurses consisted of a detailed
history and examination, including clinic BP and collection of blood
samples. The Leicestershire Research Ethics Committee approved
the study, and all subjects provided written, informed consent.
Ambulatory BP was measured with a Spacelabs 90207 monitor
(Spacelabs) for 26 hours. The first 2 hours of each record were
discarded to avoid any alerting response. The ambulatory monitor
recorded BP at 30-minute intervals between 8 AM and 9:59 PM
(“daytime”) and at 1-hour intervals between 10 PM and 7:59 AM
(“nighttime”). If ambulatory BP profiles were 80% complete, they
were repeated. We summarized the ambulatory BP data, weighting
each time period proportional to its length. The 6 phenotypic
outcomes on which our analyses focused were the time-weighted-
means of SBP and DBP for 24 hours, during the daytime, and during
the nighttime.
Further details of recruitment and phenotyping, including response
rates and measurement of clinic BP, are included in the online-only
Data Supplement.
Genotyping and Quality Assurance
We genotyped 9 WNK1 SNPs (the Figure). The choice of SNP was
informed by the results of a prior analysis of WNK1 described
elsewhere.13 In brief, 19 SNPs spanning WNK1 at 10 kb and
including all nonsynonymous coding SNPs and the SNPs immedi-
ately 5 and 3 of the gene were typed in a separate population of 100
families.13 The 9 SNPs were chosen in an initial tag SNP (tSNP)
selection by eye. In a more detailed analysis with established
criteria,14 8 of these SNPs (excluding rs2301880) were found to be
sufficient to predict common WNK1 haplotypes (minimum
Rh2100%, Rs294%) with 90% power.13 However, we present
data on all typed SNPs, including rs2301880. The WNK4
(1156666G3A) SNP10 was also typed. Genotyping for the SNPs
was done by fluorescent allelic discrimination with the ABI Prism
7900HT sequence detector system (Applera). Details are given in the
Data Supplement.
To assist in the identification of misspecified family relationships,
we also genotyped 3 highly polymorphic microsatellite markers,
d19s220, d3s1267, and d4s412, from the ABI Prism linkage mapping
set v2.5-MD10 (PE, Applied Biosystems). Details are given in the
Data Supplement. We checked for misspecified family relationships
with the PedCheck program.15 Simulation analysis in 1000 families
showed that the 3 microsatellites provided 99.3% power to detect
any mendelian inconsistency. Two complete families and 1 individ-
ual (total of 9 subjects) were excluded after showing mendelian
inconsistencies. In the remaining 996 subjects from 250 families,
using PedCheck we then searched for mendelian inconsistencies in
the SNP data attributable to genotyping error. The SNP data that
were inconsistent with mendelian inheritance (13 observations) were
coded as missing.
Statistical Analysis
Departure from Hardy-Weinberg equilibrium was tested with a 2
test on parental SNP data. We estimated |D’| and R2 measures of
linkange disequilibrium between pairs of SNPs with the JLIN
program.16
Estimates of variance components, heritability, and the effects of
individual SNPs were obtained by fitting generalized linear mixed
models (GLMMs) using Gibbs sampling in WinBUGS.17,18 These
models deal appropriately with the correlation of traits, genotypes,
and environmental exposures within families.17,18 A censored normal
approach19 was used to adjust for the effect of antihypertensive
therapy. A GLMM was fitted to estimate narrow-sense heritability
for each ambulatory BP phenotype, including age and sex (but no
genes) as covariates. The SNP covariates were then included in the
model, 1 at a time, and the effect of each SNP was estimated under
an additive genetic model. Although the GLMMs were fitted with a
Bayesian approach, flat prior distributions were used throughout, and
inferences are reported as probability values and 95% confidence
intervals (CIs).20
Using the 8 tSNPs, we also undertook a test of association of
WNK1 haplotypes with BP phenotypes in the presence of linkage by
Structure of the human WNK1 gene and location of the SNPs
analyzed. Exons are shown as vertical lines. Alternatively spliced
exons are unfilled. The locations of the SNPs typed are indi-
cated by arrows and are as follows: (1) rs1468326, (2)
rs2369402, (3) rs765250, (4) rs2286007, (5) rs880054, (6)
rs956868, (7) rs953361, (8) rs2301880, and (9) rs2286028.
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using HBAT.21 The input values for HBAT were the residuals from
a normal linear regression correcting for age and sex as covariates
and adjusting for treatment effects using a nonparametric algorithm.4
Probability values were inferred by a permutation method described
by Horvath et al,21 using up to 100 000 Monte Carlo samples.
Further details of the statistical analyses and adjustment methods
for antihypertensive treatment are available in the Data Supplement.
Results
GRAPHIC Study Families
Table 1 shows the characteristics of the 996 subjects (from
250 families) included in the analyses. Mean 24-hour ambu-
latory SBP (SD) was 119.2 (10.8), and mean ambulatory DBP
was 72.0 (7.7). There were significant correlations between
the different ambulatory BP phenotypes and also between
these phenotypes and clinic BP (Data Supplement Table I). A
history of hypertension was reported by 136 (13.7%) sub-
jects, of whom 63 (6.3%) were currently receiving antihyper-
tensive treatment.
Allele Frequencies and LD
Table 2 summarizes the genomic location, allele frequency,
and Hardy-Weinberg tests for the 9 WNK1 SNPs analyzed.
None of the SNPs showed statistically significant deviation
from Hardy-Weinberg equilibrium. Strong, pairwise LD was
observed between the intragenic SNPs from intron 1 to intron
26 (Data Supplement Figure I). The WNK4 SNP
(1156666G3A) had a minor allele frequency of 11.1% and
did not deviate from Hardy-Weinberg equilibrium (P0.62).
Heritability
The estimated proportion of the BP variance attributable to
additive polygenic effects (ie, the narrow-sense heritability,
or h2N) was 63.4% (95% CI, 52.3% to 73.3%) for mean
24-hour SBP and 67.9% (95% CI, 57.5% to 77.2%) for mean
24-hour DBP.
Primary Association Analyses
Of the 9 WNK1 SNPs, 4 exhibited a significant association
(P0.05) with mean 24-hour SBP and 5 with mean 24-hour
DBP (Table 3). Furthermore, 2 of these SNPs (rs880054 in
intron 10 and rs2301880 in intron 23) showed highly signif-
icant associations (P0.005) with mean 24-hour SBP and
DBP, respectively. In addition, rs765250 in intron 1 exhibited
a highly significant association (P0.005) with mean night-
time SBP. Under an additive genetic model, the coefficient
for each SNP (Table 3) may be interpreted as the mean
increase in BP (in mm Hg) associated with each additional
copy of the minor allele. For example, the most common SNP
rs880054 was associated with a mean reduction in 24-hour
SBP of 1.37 mm Hg per copy of the C (minor) allele (95% CI,
TABLE 1. Characteristics of the Study Participants
Variable
Parents
(n499)
Offspring
(n497)
All Subjects
(N996)
General characteristics
Male/female, n/n 250/249 250/247 500/496
Age, median (range), y 53.0 (40–60) 24.0 (18–41) 41.5 (18–60)
History of hypertension, n (%) 117 (23.4) 19 (3.8) 136 (13.7)
Current antihypertensive treatment, n (%) 62 (12.4) 1 (0.2) 63 (6.3)
Current smoker, n (%) 64 (12.8) 141 (28.4) 205 (20.6)
Weekly alcohol intake 21 units (women) and
28 units (men),† n (%)
95 (19.2) 65 (13.1) 160 (16.2)
Body mass index, mean (SD), kg/m2 27.5 (4.2) 24.8 (4.9) 26.1 (4.8)
History of high cholesterol 38 (7.6) 5 (1.0) 43 (4.3)
Diabetes, n (%) 8 (1.6) 1 (0.2) 9 (0.9)
Angina, n (%) 5 (1.0) 0 5 (0.5)
Higher education or degree-level qualifications,
n (% of respondents)*
160 (32.7) 196 (41) 356 (36.8)
Clinic BP phenotypes, mm Hg
Clinic SBP, mean (SD) 132.8 (19.2) 120.1 (15.1) 126.5 (18.4)
Clinic DBP, mean (SD) 82.9 (11.2) 73.5 (8.9) 78.2 (11.2)
Clinic BP 140/90, n (%) 191 (38.3) 61 (12.3) 252 (25.3)
Ambulatory BP phenotypes, mm Hg
24-Hour mean SBP, mean (SD) 121.1 (12.3) 117.4 (8.8) 119.2 (10.8)
24-Hour mean DBP, mean (SD) 75.0 (8.3) 69.1 (5.8) 72.0 (7.7)
Mean daytime SBP, mean (SD) 127.4 (13.4) 122.6 (9.4) 125.0 (11.8)
Mean daytime DBP, mm Hg, mean (SD) 80.2 (9.0) 74.0 (6.6) 77.1 (8.4)
Mean nighttime SBP, mm Hg, mean (SD) 112.8 (12.0) 110.7 (9.3) 111.7 (10.8)
Mean nighttime DBP, mm Hg, mean (SD) 68.2 (8.4) 62.6 (6.2) 65.4 (7.9)
*Educational level data available for 968 of the 996 subjects.
†Alcohol intake data available for 991 subjects.
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2.45-mm Hg reduction to a 0.23-mm Hg reduction). We
found no evidence of modification of the effect of any of the
WNK1 SNPs on mean 24-hour SBP or DBP by sex. The
WNK4 SNP (1156666G3A) was not associated with any of
the BP phenotypes.
Secondary Association Analyses
Secondary analyses were carried out to examine (1) the
association between WNK1 variants and clinic BP; (2) the
effect of different genetic models, and (3) the impact of
adjustments for additional covariates. Three WNK1 SNPs
were associated (P0.05) with clinic SBP and 5 with clinic
DBP (P0.00087 for association between rs880054 and
clinic DBP; Data Supplement Table II). Significant associa-
tions were observed between WNK1 SNPs and mean 24-hour
SBP and DBP under different genetic models (Data Supple-
ment Tables III to V). The data are consistent with a
codominant effect for the majority of SNPs, but a dominant
effect cannot be ruled out. Significant associations between
the WNK1 SNPs and mean 24-hour SBP and DBP were also
evident after correcting for body mass index in addition to
age and sex (Data Supplement Table VI) and also after
including a range of other covariates, such as smoking,
alcohol intake, history of hypercholesterolemia, and educa-
tional level (Data Supplement Table VII).
Haplotype Analyses of WNK1: Joint Linkage
and Association
Fifteen haplotypes with a frequency of 1% or greater were
identified, and 4 of these showed significant evidence
(P0.05) of an association in the presence of linkage with
mean 24-hour SBP and/or mean 24 hour DBP (Table 4). Of
these, 2 haplotypes were common: h2 ‘CGTCTCTC’ and h4
‘CACCCCCG’ (frequencies of 0.158 and 0.126, respec-
tively). Haplotype h2 was associated with a significant rise in
mean 24-hour DBP, whereas h4 was associated with a fall in
both mean 24-hour SBP and mean 24-hour DBP. Another
haplotype, h7 ‘CGCCTCCG’ (frequency, 0.040), was asso-
ciated with a rise in BP across all BP phenotypes, with
significant associations with 5 of the 6 ambulatory BP
TABLE 2. Description of the WNK1 SNPs Genotyped in the GRAPHIC Study
Hardy-Weinberg Test
WNK1 SNP*
Chromosome
12 Position†
WNK1
Position Alleles‡ n§
Minor-Allele
Frequency
(Parents)
Pearson’s 2
(1 df ) P
rs1468326 727762 5 region C/A 987 11.3% 0.023 0.88
rs2369402 748925 Intron 1 G/A 990 22.1% 0.046 0.83
rs765250 778544 Intron 1 T/C 990 31.1% 0.19 0.66
rs2286007 841552 Exon 8 C/T 995 8.5% 1.87 0.18
rs880054 858819 Intron 10 T/C 993 43.8% 1.37 0.24
rs956868 861173 Exon 13 C/A 992 14.2% 3.39 0.065
rs953361 872068 Intron 22 C/T 987 39.0% 1.40 0.24
rs2301880 874098 Intron 23 C/T 991 26.1% 0.55 0.46
rs2286028 885730 Intron 26 G/C 987 17.6% 0.32 0.57
*dbSNP accession number.
†Chromosome 12 position in base-pairs (source: HapMap Web site, http://www.hapmap.org/).
‡Major/minor alleles shown.
§Number of subjects with genotype data available for analysis.
Minor allele frequency and Hardy-Weinberg tests relate to the parents (parental generation).
TABLE 3. Estimates of the Effects of the WNK1 SNPs and WNK4 SNP on Ambulatory SBP and DBP Phenotypes
Mean 24-Hour SBP Mean Daytime SBP Mean Nighttime SBP Mean 24-Hour DBP Mean Daytime DBP Mean Nighttime DBP
SNP Coefficient (95% CI) P Coefficient (95% CI) P Coefficient (95% CI) P Coefficient (95% CI) P Coefficient (95% CI) P Coefficient (95% CI) P
WNK1
rs1468326 0.94 (2.65 to 0.75) 0.27 0.95 (2.85 to 0.89) 0.32 1.08 (2.84 to 0.64) 0.22 0.87 (2.02 to 0.33) 0.15 1.02 (2.30 to 0.26) 0.12 0.73 (1.84 to 0.44) 0.21
rs2369402 1.42 (2.75 to0.06) 0.037 1.42 (2.87 to0.01) 0.053 1.45 (2.77 to0.09) 0.031 0.98 (1.87 to0.04) 0.036 1.01 (2.0 to0.00) 0.044 0.90 (1.77 to0.01) 0.046
rs765250 1.50 (2.69 to0.24) 0.016 1.16 (2.52 to 0.16) 0.085 1.81 (2.91 to0.69) 0.0015 0.84 (1.70 to 0.07) 0.060 0.77 (1.68 to 0.14) 0.098 0.91 (1.71 to0.09) 0.030
rs2286007 0.80 (2.71 to 1.16) 0.42 0.42 (2.51 to 1.62) 0.70 1.16 (3.04 to 0.68) 0.23 1.05 (2.34 to 0.23) 0.11 0.99 (2.37 to 0.36) 0.16 0.97 (2.26 to 0.35) 0.14
rs880054 1.37 (2.45 to0.23) 0.015 1.48 (2.60 to0.31) 0.012 1.30 (2.44 to0.27) 0.019 1.14 (1.93 to0.38) 0.0041 1.18 (2.02 to0.33) 0.0060 1.00 (1.78 to0.20) 0.012
rs956868 1.46 (0.15 to 3.14) 0.081 1.59 (0.16 to 3.24) 0.067 1.40 (0.23 to 3.03) 0.092 0.67 (0.43 to 1.79) 0.23 0.89 (0.29 to 2.07) 0.14 0.51 (0.57 to 1.60) 0.36
rs953361 1.01 (0.11 to 2.07) 0.072 0.88 (0.29 to 2.05) 0.14 1.12 (0.03 to 2.28) 0.059 0.89 (0.10 to 1.67) 0.026 0.86 (0.02 to 1.69) 0.049 0.91 (0.18 to 1.70) 0.017
rs2301880 1.78 (3.00 to0.55) 0.0045 1.62 (3.0 to0.34) 0.017 2.0 (3.24 to0.81) 0.0012 1.07 (1.85 to0.24) 0.0099 1.05 (2.01 to0.13) 0.029 1.06 (1.95 to0.21) 0.018
rs2286028 0.99 (0.45 to 2.38) 0.17 1.12 (0.45 to 2.66) 0.16 0.93 (0.53 to 2.39) 0.19 1.00 (0.04 to 1.99) 0.039 1.08 (0.05 to 2.14) 0.041 0.98 (0 to 2.00) 0.050
WNK4
(1156666GA) 0.09 (1.67 to 1.77) 0.92 0.12 (1.74 to 1.93) 0.90 0.04 (1.70 to 1.67) 0.96 0.10 (1.12 to 1.29) 0.87 0.16 (1.15 to 1.40) 0.81 0.01 (1.22 to 1.23) 0.98
All analyses took full account of familial relationships and were adjusted for age, age2, and sex as covariates. The coefficients are shown under an additive genetic
model and may be interpreted as a per-allele effect. Significant results (P0.05) are shown in boldface type.
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phenotypes (P0.0053 for mean 24-hour DBP). In addition,
h9 ‘CGCCCCCG’ (frequency, 0.023) was associated with a
fall in BP across all phenotypes, with significant findings for
3 BP phenotypes. A multihaplotype (global) test of linkage
and association was statistically significant for mean 24-hour
DBP (P0.011) but of only borderline significance for mean
24-hour SBP (P0.058). Of interest, the 2 haplotypes with
the most discordant estimated effects were h4 and h7. These
haplotypes differed in the alleles of rs2369402 and rs880054,
which themselves showed significant associations with BP
(Table 3).
Discussion
We report statistically significant associations of common
SNPs spanning introns 1 to 26 of the WNK1 gene with
ambulatory SBP and DBP in the general population. All
SNPs that had a minor-allele frequency of 0.15 showed
significant association with at least 1 ambulatory BP
phenotype.
Any reported genetic association should be interpreted
with caution until it is replicated. However, the following
evidence supports a genuine rather than a chance or artifac-
tual association between WNK1 variants and BP. First, there
is a priori evidence of involvement of the gene in a mono-
genic form of hypertension.6 Second, power calculations
a priori and post hoc suggest that this study was adequately
powered (see Data Supplement). Third, the haplotype analy-
ses support the results of those based on the individual SNPs.
Although the GLMM-based approach is robust to stratifica-
tion and admixture,22 the haplotype analyses provide further
reassurance that these findings were not solely attributable to
population substructure.21 Fourth, although genetic associa-
tion studies should not be subject to confounding by lifestyle
factors,23 significant associations were still noted between
WNK1 SNPs and mean 24-hour SBP and DBP after correc-
tion for a range of covariates.
Although we did not apply a Bonferroni correction, our
findings cannot simply be explained by multiple testing. We
tested a limited number of WNK1 SNPs in strong LD and
found at least 1 significant association for each common SNP.
Furthermore, 2 associations with mean 24-hour BP pheno-
types and 2 associations with nighttime BP phenotypes were
highly significant (P0.005), and even the low-power global
test supported significant linkage and association of the
WNK1 haplotypes with mean 24-hour DBP (P0.011).
The GRAPHIC study adopted a design and analytic strat-
egy that optimized the ability to detect genetic determinants
of BP. First, we studied BP as a continuous trait. This is a
powerful approach, particularly when measurement error is
minimized. We therefore used ambulatory BP monitoring, the
most precise noninvasive measure of usual BP that is avail-
able. Second, through participating family practices, we
generated a study population that was representative of the
English population in terms of BP and age-appropriate
prevalence and treatment of hypertension.24,25 This sampling
strategy not only allows generalizability of the findings but
also avoids loss of power with adjustment for ascertainment
bias.26 Third, we used censored normal19 and nonparametric4
TABLE 4. Joint Linkage and Association Analysis of Haplotypes in WNK1 With Ambulatory SBP and DBP Phenotypes*
Haplotype
Mean 24-Hour
SBP
Mean Daytime
SBP
Mean Nighttime
SBP
Mean 24-Hour
DBP
Mean Daytime
DBP
Mean Nighttime
DBP
Alleles Name Frequency n† Z‡ P Z P Z P Z P Z P Z P
CGTCTCTG h1 0.175 120 0.361 0.73 0.240 0.81 0.494 0.62 0.726 0.47 0.911 0.35 0.333 0.73
CGTCTCTC h2 0.158 106 0.512 0.61 0.473 0.64 0.498 0.62 2.291 0.021 1.966 0.052 1.962 0.048
CGTCCCCG h3 0.139 98 0.206 0.84 0.233 0.81 0.049 0.96 1.403 0.16 1.207 0.23 1.555 0.12
CACCCCCG h4 0.126 84 2.264 0.025 2.230 0.023 1.854 0.064 2.159 0.032 2.142 0.032 1.512 0.14
CGTCTACG h5 0.126 80 0.663 0.51 0.843 0.40 0.271 0.78 1.287 0.20 1.146 0.26 1.103 0.27
CACTCCCG h6 0.074 58 1.847 0.059 1.980 0.047 1.391 0.17 1.210 0.22 1.030 0.30 1.245 0.21
CGCCTCCG h7 0.040 32 2.248 0.022 2.450 0.014 1.616 0.11 2.707 0.0053 2.576 0.0082 2.357 0.014
AGTCCCCG h8 0.024 21 1.592 0.11 1.010 0.32 1.646 0.095 0.471 0.64 0.086 0.94 0.437 0.66
CGCCCCCG h9 0.023 23 1.749 0.083 1.161 0.25 2.099 0.038 2.117 0.032 1.683 0.091 1.961 0.047
AGCCTCCG h10 0.016 15 0.352 0.73 0.450 0.65 0.089 0.91 0.148 0.89 0.037 0.97 0.246 0.82
CGTCCCTG h11 0.016 16 0.432 0.67 0.422 0.68 0.488 0.63 1.381 0.17 1.408 0.16 0.876 0.39
AGTCTCTC h12 0.016 16 0.055 0.95 0.402 0.70 0.615 0.55 1.213 0.23 1.46 0.15 0.283 0.78
AGTCTCTG h13 0.014 14 0.438 0.68 0.393 0.70 0.386 0.69 0.470 0.66 0.720 0.48 0.079 0.94
AGCCCCCG h14 0.012 10 1.701 0.077 2.038 0.034 0.712 0.51 0.675 0.53 1.286 0.22 0.235 0.81
AACCCCCG h15 0.010 10 0.535 0.60 0.143 0.89 0.978 0.34 0.695 0.50 0.332 0.76 0.602 0.54
Global (multihaplotype) test (P)§ 0.058 0.14 0.12 0.011 0.064 0.086
*Family-based association tests for haplotypes were used for the analysis, implemented with the HBAT extension of the FBAT toolkit.21 Significant results (P0.05)
are shown in boldface type.
†n Indicates number of informative families.
‡A negative Z score indicates a haplotype that reduces BP, and a positive Z score, a haplotype that increases BP.
§In addition to the haplotype-specific test, a more conservative global test of joint linkage and association across all haplotypes with at least 10 informative families
is shown.
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approaches to adjust for the effects of antihypertensive
therapy. These methods avoid the bias and loss in power that
arise from inappropriate correction for treatment effects.19
Fourth, the nuclear family–based design of the GRAPHIC
study permitted the study of variance components and heri-
tability and is robust to population stratification. Our esti-
mates of heritability are consistent with other studies that
have minimized the measurement error for BP.3,4
The effects of the WNK1 variants on BP may seem modest.
For example, the proportion of the additive polygenic vari-
ance in mean 24-hour SBP explained by SNP rs2301880 is
1.4% (ie, 0.9% of the total variance). However, the esti-
mated magnitude of these effects is entirely consistent with
what might be expected for a complex genetic trait. Impor-
tantly, even a 2-mm Hg-lower usual SBP is associated with
an 10% fall in stroke mortality and a 7% reduction in
mortality from ischemic heart disease or other vascular
causes in middle age.27 SNP rs2301880 exhibited a minor-al-
lele frequency of 26% and a per-allele reduction in SBP of
1.78 mm Hg, a difference of 3.5 mm Hg between TT and
CC homozygotes. The magnitude of the estimated effect is
comparable to that seen with a modest reduction in dietary
sodium.28 These observations highlight the potential public
health importance of our findings.
No other study to date has reported an association between
WNK1 variants and BP in a population-based sample.
Kokubo et al11 found no association between WNK1 SNPs
and clinic SBP or DBP in a population of 771 hypertensives
and 1047 controls selected from within the Suita cohort in
Japan. Recently, the BRIGHT study showed nominal evi-
dence of an association between WNK1 SNP rs1468326 and
SBP and DBP in a family study of extremely hypertensive
subjects.13
Only 1 common SNP has been reported in WNK4 in white
European subjects.10 This is in intron 10 (1156666GA), and
there are conflicting reports of its association with hyperten-
sion.10,12 We observed allele frequencies of this SNP similar
to those in previous studies10,12 but found no association with
either ambulatory or clinic BP in our population. We have
also confirmed that several other SNPs reported in WNK4 in
dbSNP are not polymorphic in white Europeans and have also
undertaken an SNP screening project of the promoter and
functional domains of WNK4 by direct sequencing of 20
individuals with divergent WNK1 haplotypes (S.N. and
P.B.M., unpublished data). No novel SNPs were found. Our
results are consistent with those of Erlich et al10 and suggest
that WNK4 does not contain common polymorphisms in
white Europeans.
Our study shows the potential importance of WNK1 in BP
regulation in humans. This is the first study to show that a
gene causing a monogenic form of hypertension plays a
significant role in BP regulation in the general population.
Given the function of WNK1 in renal sodium and potassium
homeostasis, it will be important to investigate whether there
are interactions between WNK1 variants with modifiable
environmental exposures, such as dietary salt intake. If such
interactions are found, then the modification of such expo-
sures may lead to a disproportionate effect in certain popu-
lation subgroups with important health consequences. Even
greater public health benefits might be realized if a more
robust understanding of the biological pathways through
which WNK1 exerts its effects leads to identification of an
intermediate phenotype that might be amenable to modifica-
tion in whole populations.23 In addition, if knowledge of the
role of WNK1 in BP regulation were to lead to the develop-
ment of antihypertensive drugs with improved efficacy or
acceptability, then substantial improvements in BP control in
the treated hypertensive population may be achieved. Given
that thiazide diuretics cause a particularly large fall in BP in
PHAII patients,9 pharmacogenetic studies to establish
whether or not the efficacy, side effects, and acceptability of
different classes of antihypertensive agents vary with poly-
morphisms in the WNK1 gene may become relevant if our
findings are confirmed in other studies.
Limitations
We studied a relatively healthy, young to middle-aged white
European population. Although BP values were broadly
representative of the English general population,25 the gener-
alizability of our findings to older age groups, less healthy
individuals, and different ethnic groups needs to be estab-
lished. Furthermore, we have not identified the causal vari-
ants in WNK1 that are responsible for the effect on BP. WNK1
is a relatively large gene, and although we assumed that the 8
tSNPs lie in a single block, it is also possible that the tSNPs
could span 1 haplotype block. The SNPs showing a
significant association spanned almost the whole WNK1 gene
(from intron 1 to intron 26), and all were intronic and unlikely
to be functional. Therefore, further investigations are required
to pinpoint specific regions of the WNK1 gene that harbor
functional genetic variants. Finally, the mechanisms by which
any causal variants in WNK1 affect BP need to be elucidated.
In summary, common variants in the WNK1 gene contrib-
ute to BP variation in the general population. The findings
provide a basis to identify functional variants of WNK1,
elucidate any interactions of these variants with dietary intake
or the response to antihypertensive drugs, and determine their
impact on cardiovascular morbidity and mortality.
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